WPI 3 (Paliperidone extended-release 3 mg)
Pill imprint WPI 3 has been identified as Paliperidone extended-release 3 mg.
Paliperidone is used in the treatment of schizoaffective disorder; schizophrenia; bipolar disorder; autism; borderline personality disorder (and more), and belongs to the drug class atypical antipsychotics. Risk cannot be ruled out during pregnancy. Paliperidone 3 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Imprint:
- WPI 3
- Strength:
- 3 mg
- Color:
- White
- Shape:
- Round
- Availability:
- Prescription only
- Drug Class:
- Atypical antipsychotics
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Actavis Pharma, Inc.
More about paliperidone
Consumer resources
- Paliperidone
- Paliperidone extended-release tablets
- Paliperidone injection
- Paliperidone (Advanced Reading)
- Paliperidone Intramuscular (Advanced Reading)
- Other brands: Invega, Invega Sustenna, Invega Trinza
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
